+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Uterine Cancer

  • ID: 4462175
  • Report
  • April 2021
  • Region: Global
  • 42 pages
  • Pharma Intelligence
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.
  • In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.
  • Merck & Co’s Keytruda and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes, respectively.
  • The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in the NDA/BLA stage.
  • Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
  • High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results for Xpovio and dostarlimab, and a PDUFA date as well as an expected European approval decision for dostarlimab.
  • The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
  • The US has a substantial lead in the number of uterine neoplasms clinical trials globally. Spain leads the major European markets, while China and Thailand share the top spot in Asia.
  • Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
  • AstraZeneca and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Hormone therapy
  • Palliative care
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Multiple Drugs for Uterine Cancer (March 19, 2021)
  • Bavencio for Uterine Cancer (May 30, 2020)
  • Trodelvy for Uterine Cancer (May 13, 2020)
  • DKN-01 for Uterine Cancer (April 23, 2020)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
  • EU Fast-Track Loss For GSK’s Dostarlimab
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Sorrento Licenses Novel ADC Approach From Mayo Clinic
  • Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
  • Tyligand Gets Onapristone ER Rights From Context
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of uterine cancer, 2019–28
Figure 2: Overview of pipeline drugs for uterine cancer in the US
Figure 3: Pipeline drugs for uterine cancer, by company
Figure 4: Pipeline drugs for uterine cancer, by drug type
Figure 5: Pipeline drugs for uterine cancer, by classification
Figure 6: Multiple Drugs for Uterine Cancer (March 19, 2021): Phase III - KEYNOTE-775 (w/Pembrolizumab)
Figure 7: Bavencio for Uterine Cancer (May 30, 2020): Phase II - TROPHIMMUN (Gestational Trophoblastic Neoplasias (GTN))
Figure 8: Trodelvy for Uterine Cancer (May 13, 2020): Phase I/II - Epithelial Cancer
Figure 9: DKN-01 for Uterine Cancer (April 23, 2020): Phase II - Gynecologic Malignancies (P204)
Figure 10: Key upcoming events in uterine cancer
Figure 11: Probability of success in the solid tumors pipeline
Figure 12: Clinical trials in uterine cancer
Figure 13: Top 10 drugs for clinical trials in uterine cancer
Figure 14: Top 10 companies for clinical trials in uterine cancer
Figure 15: Trial locations in uterine cancer
Figure 16: Uterine cancer trials status
Figure 17: Uterine cancer trials sponsors by phase

LIST OF TABLES
Table 1: Incident cases of uterine cancer, 2019–28
Table 2: Five-year prevalent cases of uterine cancer, 2019–28
Table 3: Marketed drugs for uterine cancer
Table 4: Pipeline drugs for uterine cancer in the US
Table 5: Multiple Drugs for Uterine Cancer (March 19, 2021)
Table 6: Bavencio for Uterine Cancer (May 30, 2020)
Table 7: Trodelvy for Uterine Cancer (May 13, 2020)
Table 8: DKN-01 for Uterine Cancer (April 23, 2020)
Table 9: Historical global sales, by drug ($m), 2016–20
Table 10: Forecasted global sales, by drug ($m), 2021–25
Note: Product cover images may vary from those shown
Adroll
adroll